Mauricio A Martins
Overview
Explore the profile of Mauricio A Martins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
In vivo evolution of env in SHIV-AD8-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig
OHagan D, Shandilya S, Hopkins L, Hahn P, Fuchs S, Martinez-Navio J, et al.
Mol Ther
. 2024 Dec;
33(2):560-579.
PMID: 39673132
eCD4-immunoglobulin (Ig) is an HIV entry inhibitor that mimics the engagement of both CD4 and CCR5 with the HIV envelope (Env) protein, a property that imbues it with remarkable potency...
2.
Hahn P, Martins M
J Virus Erad
. 2023 Mar;
9(1):100316.
PMID: 36915910
The ability of immunoglobulin-based HIV biologics (Ig-HIV), including broadly neutralizing antibodies, to suppress viral replication in pre-clinical and clinical studies illustrates how these molecules can serve as alternatives or adjuncts...
3.
Castro I, Ricciardi M, Gonzalez-Nieto L, Rakasz E, Lifson J, Desrosiers R, et al.
J Virol
. 2021 Apr;
95(14):e0033021.
PMID: 33910957
A prophylactic vaccine that confers durable protection against human immunodeficiency virus (HIV) would provide a valuable tool to prevent new HIV/AIDS cases. As herpesviruses establish lifelong infections that remain largely...
4.
Pedreno-Lopez N, Rosen B, Flores W, Gorman M, Voigt T, Ricciardi M, et al.
Front Immunol
. 2021 Apr;
12:657424.
PMID: 33796119
The antiviral properties of broadly neutralizing antibodies against HIV are well-documented but no vaccine is currently able to elicit protective titers of these responses in primates. While current vaccine modalities...
5.
Hangartner L, Beauparlant D, Rakasz E, Nedellec R, Hoze N, McKenney K, et al.
Sci Transl Med
. 2021 Mar;
13(585).
PMID: 33731434
Protection from immunodeficiency virus challenge in nonhuman primates (NHPs) by a first-generation HIV broadly neutralizing antibody (bnAb) b12 has previously been shown to benefit from interaction between the bnAb and...
6.
Martins M, Gonzalez-Nieto L, Ricciardi M, Bailey V, Dang C, Bischof G, et al.
J Virol
. 2020 Oct;
94(24).
PMID: 33028714
Given the complex biology of human immunodeficiency virus (HIV) and its remarkable capacity to evade host immune responses, HIV vaccine efficacy may benefit from the induction of both humoral and...
7.
Pedreno-Lopez N, Dang C, Rosen B, Ricciardi M, Bailey V, Gutman M, et al.
Mol Ther Methods Clin Dev
. 2020 Feb;
16:225-237.
PMID: 32083148
Structural characterization of the HIV-1 Envelope (Env) glycoprotein has facilitated the development of Env probes to isolate HIV-specific monoclonal antibodies (mAbs). However, preclinical studies have largely evaluated these virus-specific mAbs...
8.
Hahn A, Bischof G, Grosskopf A, Shin Y, Domingues A, Gonzalez-Nieto L, et al.
J Virol
. 2019 Oct;
94(2).
PMID: 31645449
A replication-competent, recombinant strain of rhesus monkey rhadinovirus (RRV) expressing the Gag protein of SIVmac239 was constructed in the context of a glycoprotein L (gL) deletion mutation. Deletion of gL...
9.
Gonzalez-Nieto L, Castro I, Bischof G, Shin Y, Ricciardi M, Bailey V, et al.
PLoS Pathog
. 2019 Oct;
15(9):e1008015.
PMID: 31568531
A prophylactic vaccine against human immunodeficiency virus (HIV) remains a top priority in biomedical research. Given the failure of conventional immunization protocols to confer robust protection against HIV, new and...
10.
Martins M, Bischof G, Shin Y, Lauer W, Gonzalez-Nieto L, Watkins D, et al.
Proc Natl Acad Sci U S A
. 2019 Jan;
116(5):1739-1744.
PMID: 30642966
The biological characteristics of HIV pose serious difficulties for the success of a preventive vaccine. Molecularly cloned SIVmac239 is difficult for antibodies to neutralize, and a variety of vaccine approaches...